Mindmed board of directors approves reverse share split

New york , aug. 4, 2022 /prnewswire/ -- mind medicine (mindmed) inc. (nasdaq: mnmd), (neo: mmed), (the "company" or "mindmed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that its board of directors has approved a ratio of 1-for-15 reverse share split of its common shares. as a result of the reverse share split, there will be approximately 28.4 million shares of common shares issued and outstanding1.
MNMD Ratings Summary
MNMD Quant Ranking